Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Carcinoma of the parotid Gland : A Population-Based study of incidence and treatment outcomes in 1018 patients

Sandström, K. ; Farnebo, L. ; Hafström, A. LU ; Westerborn, A. ; Olin, M. ; Hammerlid, E. ; Hammarstedt-Nordenvall, L. ; Gebre-Medhin, M. LU ; Granström, B. and Andersson-Säll, T. , et al. (2026) In Oral Oncology 174.
Abstract

Intro: Population-based studies predominantly focused on carcinoma of the parotid gland (CPG) are rare. The study aims were to analyze the incidence of CPG and to assess treatment outcomes in relation to histopathology, preoperative diagnosis and adjuvant radiotherapy. Methods: A retrospective analysis was conducted on data from the Swedish Head and Neck Cancer Register (SweHNCR), including 1,018 patients diagnosed with CPG between 2008 and 2019. Results: The age-adjusted incidence remained stable with a mean of 0.9 (range 0.65–1.08) cases per 100,000 person-years (ASR-Europe). Curative treatment was administered to 90 % of the patients, with a recurrence rate of 9 % within 3 years. The highest recurrence rates were observed in patients... (More)

Intro: Population-based studies predominantly focused on carcinoma of the parotid gland (CPG) are rare. The study aims were to analyze the incidence of CPG and to assess treatment outcomes in relation to histopathology, preoperative diagnosis and adjuvant radiotherapy. Methods: A retrospective analysis was conducted on data from the Swedish Head and Neck Cancer Register (SweHNCR), including 1,018 patients diagnosed with CPG between 2008 and 2019. Results: The age-adjusted incidence remained stable with a mean of 0.9 (range 0.65–1.08) cases per 100,000 person-years (ASR-Europe). Curative treatment was administered to 90 % of the patients, with a recurrence rate of 9 % within 3 years. The highest recurrence rates were observed in patients with salivary duct carcinoma and adenocarcinoma, while patients with acinic cell and mucoepidermoid carcinomas had lower recurrence rates. For stage I–II tumors, the 5-year relative survival was unaffected by whether the malignant diagnosis was known preoperatively. Male sex, increasing age, stage III–IV disease, and a World Health Organization/ Eastern Cooperative Oncology Group (WHO/ECOG) performance status 2–4 was independently associated with increased overall mortality risk, whereas the timing of adjuvant radiotherapy was not. Conclusion: This study contributes to establishing the incidence and treatment outcomes of CPG in Sweden and highlights the diverse histopathological diagnoses of these tumors. Notably, unknown malignancy at the time of surgery did not impact survival in early-stage disease, and the timing of postoperative radiotherapy was not associated with overall survival.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Carcinoma, Histopathology, Postoperative radiotherapy, Preoperative diagnosis, Salivary gland, Survival, SweHNCR
in
Oral Oncology
volume
174
article number
107863
publisher
Elsevier
external identifiers
  • pmid:41579652
  • scopus:105028281669
ISSN
1368-8375
DOI
10.1016/j.oraloncology.2026.107863
language
English
LU publication?
yes
id
a0aa0780-7f9c-482f-894d-0c802c83a556
date added to LUP
2026-02-18 12:54:09
date last changed
2026-05-28 03:11:09
@article{a0aa0780-7f9c-482f-894d-0c802c83a556,
  abstract     = {{<p>Intro: Population-based studies predominantly focused on carcinoma of the parotid gland (CPG) are rare. The study aims were to analyze the incidence of CPG and to assess treatment outcomes in relation to histopathology, preoperative diagnosis and adjuvant radiotherapy. Methods: A retrospective analysis was conducted on data from the Swedish Head and Neck Cancer Register (SweHNCR), including 1,018 patients diagnosed with CPG between 2008 and 2019. Results: The age-adjusted incidence remained stable with a mean of 0.9 (range 0.65–1.08) cases per 100,000 person-years (ASR-Europe). Curative treatment was administered to 90 % of the patients, with a recurrence rate of 9 % within 3 years. The highest recurrence rates were observed in patients with salivary duct carcinoma and adenocarcinoma, while patients with acinic cell and mucoepidermoid carcinomas had lower recurrence rates. For stage I–II tumors, the 5-year relative survival was unaffected by whether the malignant diagnosis was known preoperatively. Male sex, increasing age, stage III–IV disease, and a World Health Organization/ Eastern Cooperative Oncology Group (WHO/ECOG) performance status 2–4 was independently associated with increased overall mortality risk, whereas the timing of adjuvant radiotherapy was not. Conclusion: This study contributes to establishing the incidence and treatment outcomes of CPG in Sweden and highlights the diverse histopathological diagnoses of these tumors. Notably, unknown malignancy at the time of surgery did not impact survival in early-stage disease, and the timing of postoperative radiotherapy was not associated with overall survival.</p>}},
  author       = {{Sandström, K. and Farnebo, L. and Hafström, A. and Westerborn, A. and Olin, M. and Hammerlid, E. and Hammarstedt-Nordenvall, L. and Gebre-Medhin, M. and Granström, B. and Andersson-Säll, T. and Laurell, G.}},
  issn         = {{1368-8375}},
  keywords     = {{Carcinoma; Histopathology; Postoperative radiotherapy; Preoperative diagnosis; Salivary gland; Survival; SweHNCR}},
  language     = {{eng}},
  publisher    = {{Elsevier}},
  series       = {{Oral Oncology}},
  title        = {{Carcinoma of the parotid Gland : A Population-Based study of incidence and treatment outcomes in 1018 patients}},
  url          = {{http://dx.doi.org/10.1016/j.oraloncology.2026.107863}},
  doi          = {{10.1016/j.oraloncology.2026.107863}},
  volume       = {{174}},
  year         = {{2026}},
}